SUPN (Supernus Pharma) EV/EBITDA Multiple
Supernus Pharmaceuticals (SUPN) relies on the success of new drugs and patent protection within the CNS field. The company's environmental footprint is minimal due to strict control of office waste. Revenues are based on the sales of high-margin drugs Qelbree and Trokendi XR. This chart from the GURU.Markets platform illustrates the change in the company's EV/EBITDA level, where 10.16 reflects the current value of this multiple.
Metric breakdowns and analytics for supernus.com (SUPN)
- market price and analyst price targets:
- business market valuation indicators:
- issuer book value statistics:
- debt and liquidity data:
- business earnings and investment ratios data:
SUPN - Final Profit|Projected Future Earnings Supernus Pharmaceuticals|SUPN - P/E Multiple|Future Price to Earnings Supernus Pharmaceuticals|SUPN - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Supernus Corp|SUPN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Supernus|SUPN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth supernus.com|SUPN - Net earnings per share growth this year|Earnings growth forecast for next year Supernus Pharmaceuticals
- company sales and revenue statistics:
Comprehensive company analysis:Supernus Pharma (SUPN)
For the Supernus Pharmaceuticals (SUPN) pharma ecosystem, which focuses on CNS therapy, this ratio serves as a measure of business value relative to its operating efficiency before interest and taxes. By analyzing the historical EV/EBITDA trend of Supernus Pharmaceuticals (SUPN), an investor can determine the fairness of the asset's market valuation amid the expansion of the pediatric segment and risks of patent expiration, allowing for the timely identification of overvalued or undervalued shares.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|NBIX (Neurocrine Corp) - Company Value to Operating Income Before Depreciation Ratio|Regencell Bioscience - EV/EBITDA Multiple|Company Value to EBITDA axsome.com|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Xenon Pharmaceuticals Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Enterprise Value to Operating Income Before Depreciation CPRX (Catalyst Corp)|Enterprise Value to EBITDA Ratio DNLI (Denali Therapeutics)|EV/EBITDA Multiple harmonybiosciences.com (HRMY)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biohaven BHVN|Total Company Value to Operating Income Before Depreciation Ratio Amylyx Pharmaceuticals Inc (AMLX)|TRVI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation PRAX (Praxis Corp)|Anavex Life Sciences (AVXL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CBLL (ceribell.com)|PRTA (Prothena Corporation plc) - EV/EBITDA Multiple|ALEC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANNX|EV/EBITDA Multiple omeros.com (OMER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Inc. NGNE|Business Value to Operating Income Before Depreciation ACIU|VYGR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Neumora (NMRA) - Enterprise Value to EBITDA Ratio|SCLX: EV/EBITDA Multiple|Tevogen Bio Inc. (TVGN) - EV/EBITDA Multiple|ACOG (Alpha Cognition Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cogrx.com (CGTX)|EV/EBITDA Multiple IKT|SAVA - Company Value to EBITDA|Assertio - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Coya Therapeutics Inc COYA|VTGN: Enterprise Value to EBITDA Ratio|Ovid Therapeutics Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|ABOS: EV/EBITDA Multiple|CRVO - Total Company Value to Operating Income Before Depreciation Ratio|ATHE (Alterity Therapeutics Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Clene Nanomedicine (CLNN)|EV/EBITDA Multiple PEPG|EV/EBITDA Multiple jupiterneurosciences.com (JUNS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|Annovis Bio Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Firefly Neuro AIFF|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NRSN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio RVPH|EV/EBITDA Multiple MetaVia, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ATHA (Athira Pharma Inc) - Enterprise Value to Operating Income Before Depreciation|ADXN: EV/EBITDA Multiple|Company Value to EBITDA Alzamend Neuro (ALZN)|Enterprise Value to EBITDA Ratio CYCN|EV/EBITDA Multiple Protagenic|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BrainStorm Cell Therapeutics Inc. (BCLI) - Company Value to EBITDA|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio chromocell.com CHRO|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|Intra-Cellular Therapies, Inc. (ITCI) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Marinus Pharma - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NKGN|NRBO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|Business Value to Operating Income Before Depreciation SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIGL (Vigil Neuroscience) - Enterprise Value to Operating Income Before Depreciation|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|cerevel.com (CERE) - EV/EBITDA Multiple
